Does Humana Cover Prolia? A Complete Insurance Guide for 2025

What Is Prolia and Why Do Doctors Prescribe It?

Prolia is a RANK-ligand inhibitor that reduces bone resorption by blocking osteoclast formation. The FDA approved denosumab 60 mg (Prolia) in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the label was later expanded to include men with osteoporosis, patients on glucocorticoid therapy, and individuals losing bone mass because of androgen-deprivation or aromatase-inhibitor therapy [1].

The FREEDOM trial (N=7,808) demonstrated that denosumab reduced new vertebral fractures by 68% (relative risk reduction), hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [2]. Those numbers explain why the Endocrine Society's 2019 clinical practice guideline lists denosumab as a first-line pharmacological option for postmenopausal women with osteoporosis who have a high fracture risk or who cannot tolerate oral bisphosphonates [3].

Because Prolia is given as a subcutaneous injection in a clinical setting every 6 months rather than taken as a daily or weekly pill, its billing and insurance pathway differs from most osteoporosis drugs. That distinction shapes exactly how Humana covers it.

How Humana's Coverage Pathways Work for Prolia

Prolia reaches Humana members through two distinct billing pathways, and getting this wrong can result in a surprise bill. The pathway that applies to you depends on your specific plan type.

Medicare Advantage (Part C) members. When a physician, nurse practitioner, or other qualified provider administers Prolia in an office, outpatient clinic, or infusion center, the claim typically runs through the medical benefit under Medicare Part B rules. CMS classifies denosumab (HCPCS code J0897) as a Part B drug when it is administered by a provider [4]. Humana Medicare Advantage plans must cover all services that original Medicare Part B covers, so Prolia administered in-office qualifies. Your cost-sharing is usually 20% of the Medicare-approved amount after the Part B deductible, though many Humana MA plans cap out-of-pocket costs below that level.

Stand-alone Part D or commercial plan members. If your plan uses a pharmacy benefit for Prolia, the drug lands on a specialty tier. Most Humana Part D formularies place Prolia on Tier 4 or Tier 5, which carries the highest cost-sharing percentage. A specialty-tier copay can range from 25% to 33% of the negotiated drug price [5]. A specialty pharmacy typically ships the prefilled syringe to the prescribing office or directly to a patient.

Important: A small number of Humana commercial employer-sponsored plans split the benefit differently. Always confirm with Humana member services (1-800-448-6262) and your prescribing provider's billing team which pathway your plan uses before the first injection.

Prior Authorization Requirements for Prolia Under Humana

Prior authorization (PA) is not optional on any major Humana plan that covers Prolia. Humana's PA criteria for denosumab generally require the prescriber to document all of the following:

1. A dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck, OR a documented fragility fracture, OR a FRAX 10-year major osteoporotic fracture probability of 20% or higher (consistent with National Osteoporosis Foundation thresholds) [6].
2. Confirmation that the patient meets an FDA-approved indication for Prolia.
3. For most plans, documentation that the patient has either tried and failed, or has a clinical contraindication to, at least one oral bisphosphonate (alendronate or risedronate) [7].
4. A prescriber attestation that calcium and vitamin D supplementation are in place, or a documented clinical reason they are not appropriate. The NOF recommends 1,000 to 1 to 200 mg calcium daily and 800 to 1 to 000 IU vitamin D daily for adults at fracture risk [8].

Humana typically responds to PA requests within 72 hours for non-urgent cases. Your provider's office submits the PA through Humana's online portal or by fax, accompanied by the DXA report, the most recent bone-related lab results, and the office note documenting the diagnosis.

The HealthRX clinical team has identified a five-step prior authorization framework that reduces Prolia PA denials across major insurers including Humana:

Step 1. Obtain a DXA scan and calculate FRAX before submitting the PA. A FRAX score strengthens the clinical justification even when the T-score alone meets threshold.

Step 2. Document any bisphosphonate trial. If the patient experienced GI intolerance, esophageal irritation, or atypical femur fracture risk on alendronate, state the specific adverse event and duration of trial in the chart note.

Step 3. Confirm the HCPCS code (J0897) and place of service code in the PA request match the intended administration site.

Step 4. Attach the full DXA report, not just the summary T-score. Humana's clinical reviewers frequently cite incomplete documentation as the primary reason for initial denial.

Step 5. Request the PA approval in writing and confirm it covers the full 12-month treatment period (two injections), not just the first dose.

What Prolia Costs Humana Members With and Without Prior Authorization

Without insurance, a single Prolia injection (60 mg/mL prefilled syringe) carries a list price of approximately $1,400 to $1 to 600 in 2025. Two injections per year brings the annual cost to roughly $2,800 to $3,200 before any negotiated discounts [9].

With an approved Humana Part B claim, the Medicare-approved amount is typically lower than list price. Your out-of-pocket responsibility under original Medicare rules is 20% of the approved amount after the Part B deductible ($257 in 2025). Many Humana Medicare Advantage plans further reduce that copay or apply it to their annual out-of-pocket maximum, which the ACA caps at $9,350 for in-network services in 2025 for Medicare Advantage plans.

Amgen, the manufacturer of Prolia, operates a patient assistance program called Amgen SupportPlus. Commercially insured patients who meet income criteria may pay as little as $0 per injection through this program [10]. Medicare beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback rules, but they may qualify for Amgen's free-drug program if household income is at or below 500% of the federal poverty level.

The Inflation Reduction Act of 2022 introduced Medicare Part D out-of-pocket caps. Starting in 2025, Part D enrollees pay no more than $2,000 out of pocket annually for covered drugs, which benefits patients on specialty-tier Prolia under a pharmacy benefit [11].

What Happens If Humana Denies Coverage for Prolia

A denial is not the end of the road. Humana, like all Medicare Advantage plans, must follow CMS-defined appeals timelines [12].

Level 1 appeal (redetermination). Your provider resubmits with additional clinical documentation. Humana must respond within 60 days for standard appeals or 72 hours for expedited appeals when the standard timeline could seriously jeopardize health.

Level 2 appeal (reconsideration by Qualified Independent Contractor). If Humana upholds the denial, an independent reviewer examines the case. The QIC must respond within 60 days (standard) or 72 hours (expedited).

Levels 3 through 5. Further appeals go to an Administrative Law Judge, the Medicare Appeals Council, and finally federal district court. Fewer than 5% of cases reach Level 3, because most are resolved at Level 1 or 2 with complete documentation [13].

If the denial was based on a step-therapy (bisphosphonate-first) requirement and your physician believes starting with Prolia is clinically appropriate, your doctor can request a step-therapy exception. CMS regulations require Medicare Advantage plans to grant exceptions when a step-therapy drug is contraindicated, previously tried and failed, or when the plan drug is not in the patient's best clinical interest [14].

Alternatives to Prolia Covered by Humana

If Prolia is denied or cost-sharing is prohibitive, several other osteoporosis treatments may be covered at lower cost tiers.

Alendronate (generic Fosamax) is available for as little as $4 to $10 per month at most pharmacies and sits on Tier 1 or Tier 2 of virtually every Humana formulary [15]. The FDA approved alendronate for postmenopausal osteoporosis in 1995, and it reduces vertebral fracture risk by approximately 47% and hip fracture risk by 51% in women with prior vertebral fractures, per the FIT trial [16].

Risedronate (generic Actonel) offers a similar bisphosphonate mechanism. The VERT-MN trial showed a 41% relative reduction in new vertebral fractures over 3 years [17].

Zoledronic acid (Reclast), an annual intravenous bisphosphonate, is covered under Humana Part B as a physician-administered infusion. The HORIZON Key Fracture Trial (N=7,765) showed zoledronic acid 5 mg IV annually reduced hip fractures by 41% and vertebral fractures by 70% over 36 months [18]. Annual IV therapy can suit patients with GI intolerance to oral bisphosphonates.

Romosozumab (Evenity), a sclerostin inhibitor, and teriparatide (Forteo), a PTH analog, are high-cost biologics reserved for severe or treatment-refractory osteoporosis. Both require PA under Humana and typically require a documented failure on a bisphosphonate before approval [19, 20].

The American Association of Clinical Endocrinology 2020 guidelines state: "Sequential therapy planning is essential; patients who discontinue denosumab must transition to a bisphosphonate to prevent rapid bone loss and rebound fracture risk" [21]. That guidance matters for Humana PA requests because it supports the case for Prolia in patients who have already tried bisphosphonates.

Verifying Your Specific Humana Plan's Prolia Coverage

Formularies change each January 1. A plan that covered Prolia in 2024 may have adjusted cost-sharing or tier placement for 2025. The most reliable way to confirm current coverage is to:

1. Pull your Evidence of Coverage (EOC) document from your Humana online account.
2. Search Humana's online Drug Finder tool at humana.com using your plan ID and "denosumab" or "Prolia."
3. Call Humana member services at 1-800-448-6262 and ask specifically whether denosumab J0897 is covered under your medical benefit or pharmacy benefit, what tier it occupies, and whether PA is required.
4. Ask your prescriber's billing department to run a benefit investigation before scheduling the injection appointment.

Benefit investigations take 24 to 48 hours and confirm the exact cost-sharing amount before you commit to a treatment date.

What Clinicians Say About Prescribing Prolia to Insured Patients

Dr. E. Michael Lewiecki, Director of the New Mexico Clinical Research and Osteoporosis Center and a past president of the National Osteoporosis Foundation, has written: "Denosumab is an effective therapy for osteoporosis, but its unique mechanism means that discontinuation without transitioning to another antiresorptive carries serious fracture risk. Prescribers and insurers both need to plan for continuity of therapy, not just initial approval" [22].

That clinical context matters for insurance purposes. Because stopping Prolia abruptly can cause rapid bone loss and multiple vertebral fractures within 12 to 18 months of the last dose, continuity of coverage is a patient-safety issue, not merely a convenience [23]. A single denied renewal PA can have clinical consequences that go well beyond the administrative hassle. If a Humana plan changes its PA requirements at renewal, the prescribing physician should submit the renewal PA at least 60 days before the 6-month injection is due.

Bone Density Monitoring Requirements and Coverage

Humana covers DXA scans under Medicare Part B every 24 months for beneficiaries who meet at least one of the following criteria: postmenopausal women who are not taking estrogen, individuals with vertebral abnormalities, patients on long-term glucocorticoid therapy equivalent to 7.5 mg prednisone per day or more for 3 months or longer, individuals with primary hyperparathyroidism, or patients being monitored for response to FDA-approved osteoporosis drug therapy [24].

A repeat DXA scan is often required to document response to Prolia therapy when submitting a PA renewal. The USPSTF recommends DXA screening for all women 65 and older and for younger postmenopausal women whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors [25].

Vitamin D deficiency is common in osteoporosis patients and can confound both DXA results and treatment response. The NIH Office of Dietary Supplements reports that approximately 35% of U.S. adults have vitamin D levels below 50 nmol/L [26]. Humana covers serum 25-hydroxyvitamin D testing (CPT 82306) under most plans, and documenting a normal or corrected vitamin D level before starting Prolia strengthens the PA submission.

Special Populations: Humana Coverage for Prolia Beyond Postmenopausal Osteoporosis

Prolia's FDA-approved label covers several populations beyond postmenopausal women. Humana's PA criteria extend to these groups when documentation is complete.

Men with osteoporosis. The FDA approved Prolia for men with osteoporosis at high fracture risk in 2012 based on a trial showing significant BMD gains at the lumbar spine (5.7% vs. 0.9% placebo) and femoral neck (2.4% vs. 1.0% placebo) at 24 months [27].

Glucocorticoid-induced osteoporosis (GIOP). Patients on glucocorticoid therapy of at least 7.5 mg prednisone daily for 6 months or longer qualify. The FDA expanded the Prolia label for GIOP in 2018 after a trial showed greater BMD gains compared with risedronate at lumbar spine (6.9% vs. 0.8%) at 12 months [28]. The ACR's 2022 GIOP guidelines support denosumab as an option for patients at high fracture risk on long-term glucocorticoids [29].

Hormone-ablation bone loss. Men receiving androgen-deprivation therapy (ADT) for prostate cancer and women on aromatase inhibitors (AI) for breast cancer lose bone rapidly. Both groups fall under Prolia's approved indications. Humana oncology benefit managers handle these cases; the prescriber should specify the underlying cancer treatment and resulting bone loss in the PA.

Key Takeaway for Patients and Prescribers

Humana covers Prolia for most members who meet the FDA-approved indications, but prior authorization documentation must be complete and specific. Confirm whether your plan routes the claim through Part B or Part D, submit the DXA report and FRAX score with the PA, document any prior bisphosphonate trial, and plan the renewal PA at least 60 days before the next injection is due. For Medicare Part D members, the 2025 $2,000 annual out-of-pocket cap under the Inflation Reduction Act meaningfully limits exposure to Prolia's specialty-tier cost-sharing.